Automated Electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals by C. Prontera et al.
published own observations); and (c)
6-TGNs are considered the active
thiopurine metabolites, whereas the
role of 6-methyl-mercaptopurine for
therapeutic drug monitoring is still a
matter of debate (except for compli-
ance).
We agree that oxidation of the
thiopurine thiol moiety is also a crit-
ical point in the analysis of thionucle-
otide metabolites. This point cer-
tainly requires more attention when
method harmonization is intended.
Although we concentrated on the
hydrolysis step, we addressed the
question of oxidation in our inves-
tigation by including a set of experi-
ments on the effect of increasing
concentrations of the antioxidant di-
thiothreitol on 6-thio-guaninc (6-TG)
recovery. Higher dithiothreitol con-
centrations were associated with en-
hanced 6-TG recovery (1 ).
The aim of our publication was to
draw attention to method-dependent
therapeutic ranges that preclude a
comparison of results from clinical
studies based on different methods.
A considerable number of methods
for the measurement of 6-TGNs have
been published, and new methods or
modifications of existing assays are
still being generated. As discussed in
our report, these methods differ in
several analytical steps, including
the choice of matrix, the analytical
procedure, and the way results are
reported. However, these new or
modified methods have usually not
been compared with an established
procedure. In addition, there is un-
fortunately no external quality-
control system available that could
provide information about compara-
bility of results. The major problems
for a real standardization include the
lack of a reference method and an
approved and appropriate reference
material such as a 6-TGN standard.
We also agree that the matter is com-
plicated by the fact that the product
of drug metabolism in vivo is a mix-
ture of mono-, di-, and triphosphates.
However, according to our experi-
ence, many physicians involved in
the care of patients receiving thiopu-
rine drugs, as well as laboratories
involved in therapeutic drug moni-
toring of these patients, do not have
sufficient information about the
method dependency of the reported
6-TGN concentrations and may be
misled when comparing individual
values with therapeutic ranges de-
rived from the literature. To improve
the comparability between the differ-
ent methods, it is therefore important
that efforts be made to find a consen-
sus on the analytical conditions as
well as the format of result reporting.
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Natriuretic Peptides (NPs):
Automated Electrochemiluminescent
Immunoassay for N-Terminal pro-BNP
Compared with IRMAs for ANP and
BNP in Heart Failure Patients and
Healthy Individuals
To the Editor:
We evaluated the performance and
diagnostic accuracy of an electro-
chemiluminescence immunoassay
(ECLIA) method for N-terminal pro-
B-type natriuretic peptide (NT-
proBNP) in healthy persons and in
patients with cardiac disease, and
then compared the results obtained
with the ECLIA method with results
from IRMA methods for BNP and
atrial natriuretic peptide (ANP).
We studied 58 healthy individuals
[mean (SD) age, 58 (8) years; 19
women and 39 men] and 148 consec-
utive patients [mean age, 64 (13)
years; range, 20–80 years; 47 women
and 101 men] with cardiomyopathy,
admitted to the Department of Car-
diovascular Medicine of our Insti-
tute. The study was done from No-
vember 2001 to October 2002. All
healthy participants were nonobese,
normotensive, and free from acute
diseases, and all denied the use of
any drug during the 4 weeks before
the study. All had normal values for
the main plasma indices and non-
pathologic erythrocyte and leukocyte
counts and urine analysis. In all of
the participants, a complete cardio-
logic examination, including electro-
cardiogram and echocardiographic
investigation (left ventricular ejec-
tion fraction 55%), was performed;
in patients50 years of age, an effort
stress test was performed to exclude
asymptomatic heart disease. Cardiac
morphology and function were as-
sessed in all patients by Doppler
echocardiography, radionuclide ven-
triculography, or cardiac catheteriza-
tion, when needed. Primary dilated
cardiomyopathy was found in 95 pa-
tients, whereas the other 53 patients
suffered from secondary cardiomy-
opathy; of these, 38 had ischemic
cardiomyopathy. A total of 22 pa-
tients were in functional New York
Heart Association (NYHA) class I, 72
in class II, and 54 in class III-IV; the
mean (SD) left ventricular ejection
fraction was 31.4 (9.6)%.
NT-proBNP was measured by a
fully automated “sandwich” ECLIA
method using an Elecsys 2010
analyzer (Roche Diagnostics). This
ECLIA is based on two polyclonal
antibodies: a biotinylated antibody
and a ruthenium derivative-labeled
antibody. Total duration of assay
was 18 min. Plasma ANP and BNP
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were measured with two-site IRMA
methods, previously set up in our
laboratory, as described elsewhere in
detail (1, 2). We assayed blood sam-
ples (10 mL), collected into ice-
chilled disposable polypropylene
tubes containing aprotinin (500 kIU/
mL of plasma) and EDTA (1 g/L of
plasma), in such a way as to use the
same samples for all three assays,
even if the addition of plasma pro-
tease inhibitors (such as aprotinin)
was not necessary for NT-proBNP
assay. Plasma samples were rapidly
separated by centrifugation for 15
min at 4 °C, and then were frozen
and stored at 20 °C in 1-mL ali-
quots in polypropylene tubes until
assay.
Within-run and total imprecisions
were tested following the guideline
approved by NCCLS (3 ) by repeat-
edly measuring two plasma samples
on 20 different working days with
NT-proBNP concentrations in the
upper part of the reference interval
(e.g., 103.8 ng/L) and the lower part
of abnormal values (e.g., 601.7 ng/L;
typical of patients with only moder-
ate heart failure), in such a way as to
better evaluate the imprecision in the
discrimination zone between healthy
individuals and patients with cardiac
disease. Within-run imprecisions
(CV) were 1.7% and 1.8%, and total
imprecisions were 4.0% and 3.8%, for
the two samples, respectively. These
data indicate that ECLIA for NT-
proBNP measures peptide concen-
trations in the discrimination zone
between healthy participants and pa-
tients with cardiac disease with an
imprecision better than that of ANP
and BNP assays (1, 2).
Peptide concentrations of patients
with cardiomyopathy were much
higher than those of healthy partici-
pants and progressively increased
with disease severity (as measured:
in healthy participants, 51.6 (34.6)
ng/L; in NYHA class I, 367.0 (349.9)
ng/L; NYHA class II, 1376.4 (1590.4)
ng/L; NYHA class III, 5297.9 (6373.6)
ng/L; NYHA class IV, 8421.1 (9231.1)
ng/L). Moreover, we tested and
compared the different degrees of
diagnostic accuracy for ANP, BNP,
and NT-proBNP assays in discrimi-
nating between the group of healthy
participants and the group of pa-
tients with heart failure by ROC
analysis using the “bootstrap percen-
tile method” with 1000 bootstrap
replications (Table 1). Our data indi-
cate that NT-proBNP assay perfor-
mance is better than that of both
ANP and BNP assays in discriminat-
ing diseased from healthy individu-
als. In particular, the better perfor-
mance of NT-proBNP ECLIA is more
evident when patients with only
mild heart failure (NYHA class I and
II) are considered in the ROC analy-
sis (Table 1). Of course, this finding is
of great clinical relevance when con-
sidering that NT-proBNP could be
used as a screening test for the diag-
nosis of chronic heart failure. How-
ever, it is important to note that a
recent report (4 ) indicated pitfalls in
community screening for left ventric-
ular dysfunction when IRMA meth-
ods were used for the assay of BNP
and NT-proANP in asymptomatic
individuals, particularly in women.
Our findings cannot indicate
whether the improved clinical per-
formance of NT-proBNP compared
with the two other cardiac natriuretic
hormone (CNH) assays is a result of
its better assay precision or a true
larger separation of NT-proBNP dis-
tribution values in healthy and pa-
tient populations than those of ANP
and BNP. To address this important
issue, we need to compare the per-
formance of the NT-proBNP ECLIA
method with that of a new genera-
tion of BNP assays (5, 6). In this
regard, a previous study (7 ), which
used a different immunoassay for
NT-proBNP, showed no significant
Table 1. ROC analysis.a
AUCb 95% CI AUC P
Optimal
cutoff, ng/L
Sensitivity
(at cutoff), %
Specificity
(at cutoff), %
Healthy individuals (n  58) vs all
patients with heart failure (n  148)c
ANP 0.862 0.809–0.908 0.001 27.53 74 96
BNP 0.922 0.884–0.954 0.001 71.15 77 96
NT-proBNP 0.957 0.925–0.981 0.001 2425.7 91 95
Healthy individuals (n  58) vs patients
with mild heart failure
(NYHA class I–II; n  94)d
ANP 0.789 0.708–0.859 0.001 20.28 63 96
BNP 0.881 0.819–0.935 0.001 116.24 74 90
NT-proBNP 0.933 0.88–0.971 0.001 641.17 88 93
Healthy individuals (n  58) vs patients
with severe heart failure
(NYHA class III–IV; n  54)e
ANP 0.989 0.974–0.998 0.001 15.90 92 93
BNP 0.922 0.974–1.000 0.001 36.92 96 98
NT-proBNP 0.957 0.993–1.000 0.001 618.81 96 98
a Ref. (10).
b AUC, area under the curve; CI, confidence interval.
c AUC comparisons: ANP vs BNP, P  0.037; ANP vs proBNP, P 0.0001; BNP vs proBNP, P 0.0001.
d AUC comparisons: ANP vs BNP, P  0.028; ANP vs proBNP, P 0.0001; BNP vs proBNP, P 0.0001.
e AUC comparisons: ANP vs BNP, P  0.72 (not significant); ANP vs proBNP, P  0.078 (not significant); BNP vs proBNP, P  0.04.
Clinical Chemistry 49, No. 9, 2003 1553
differences from the clinical results
respectively obtained with NT-
proBNP and BNP assays, thus sug-
gesting that the performance of the
immunoassays used may a very cru-
cial point in determining the results
of a clinical study comparing differ-
ent CNH assays.
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Biological Variation of N-Terminal Pro-
Brain Natriuretic Peptide in Healthy
Individuals
To the Editor:
Brain natriuretic peptide (BNP) and
its N-terminal prohormone (NT-
proBNP) fragment have been shown
to be effective in diagnosing left ven-
tricular dysfunction (1, 2), and in
particular, they have a strong nega-
tive predictive value (3 ). NT-proBNP
and the hormone are secreted on an
equimolar basis, but NT-proBNP
lacks a clearance receptor. It there-
fore has a longer half-life in serum
than the active hormone does, and its
circulating concentration is believed
to be less influenced by the condi-
tions under which the blood sample
is taken.
Information on the biological vari-
ation of NT-proBNP is not available;
this is limiting because the clinical
utility of laboratory data can be af-
fected by physiologic variation (4 ).
Here we report the results of a study
to determine the biological variabil-
ity of NT-proBNP.
Five blood specimens were col-
lected from each of 16 apparently
healthy laboratory workers (5 men
and 11 women; age range, 43–62
years) twice a week (Tuesdays and
Fridays) over a 17-day period. None
of the workers smoked, took any
medication, or consumed substantial
quantities of alcohol. In accordance
with Helsinki Declaration II, the de-
sign and execution of the experiment
were explained thoroughly to the
participants, and informed consent
was obtained. Blood was collected
under standardized conditions to
minimize sources of preanalytic vari-
ation. After an overnight fast, a blood
specimen was taken by conventional
venipuncture between 0800 and 0900
with the volunteers in the sitting
position, avoiding venous stasis. All
samples were drawn by the same
phlebotomist, allowed to clot, and
then centrifuged at 3000g for 15 min
at room temperature within 1 h of
collection. Sera were separated and
stored at 70 °C until analysis. It has
been documented that the N-termi-
nal peptide can be safely stored fro-
zen at 20 and 80 °C for at least 3
months (5 ).
At the end of the collection period,
all frozen samples were thawed,
mixed, and centrifuged for analysis
in a single run in duplicate. NT-
proBNP concentrations were deter-
mined by an electrochemilumines-
cence sandwich immunoassay
(Roche Diagnostics). The assay was
performed on an Elecsys System
2010 by the same analyst, who fol-
lowed the assay manufacturer’s rec-
ommendations. After exclusion of
one outlier and logarithmic transfor-
mation of the data (required because
of the skewed distributions of the
NT-proBNP data), the analytical
(CVA) and intra- (CVI) and interindi-
vidual (CVG) components of varia-
tion were calculated by nested
ANOVA. We also calculated the crit-
ical difference for significant changes
in serial results (P 0.05), the index
of individuality, the number of spec-
imens required to estimate the ho-
meostatic setpoint of an individual
(within  10% with a confidence of
95%), and the desirable quality spec-
ifications for imprecision (I), bias (B),
and total error (TE), which were
calculated using the formulas: I 
0.5CVI; B  0.25 (CVI
2  CVG
2)1/2;
and TE  1.65 I  B ( 0.05). The
results are reported in Table 1.
Minor, not statistically significant
differences (P 0.87), were observed
between genders and were attribut-
Table 1. Mean values; estimated mean analytical (CVA), intraindividual (CVI),
and interindividual (CVG) variation; and derived indices for serum NT-proBNP.
Group
Mean,
pmol/L
CVA,
%
CVI,
%
CVG,
% IIa
Desirable quality specifications
CD, %
No. of
specimens
Imprecision,
%
Bias,
%
Total
error, %
All 8.37 2.7 9.1 14 0.64 4.6 4.22 11.72 26.33 3
Men 9.42 1.1 6.5 16 0.41 3.2 4.29 9.65 18.18 2
Women 7.98 3.1 10 14 0.71 5.0 4.32 12.57 29.04 4
a II, index of individuality; CD, critical difference.
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